poisar

Stocks · News reference

Cantor Fitzgerald Maintains Buy Rating on Novavax

Analyst Pete Stavropoulos at Cantor Fitzgerald has reaffirmed a 'Buy' rating and a $18 price target for Novavax, Inc.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NVAX
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Josh Kohn-Lindquist

    Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

    Moderna's stock fell 18% after reports of a data leak regarding its personalized melanoma vaccine showed a 42% reduction in recurrence or death risk when paired with Merck's Keytruda—lower than Phase II results of 49%. The full Phase 3 results were scheduled for release on October 24, and the leaked figures fell short of market expectations despite the company's 600% gain in 2026.

    MRNAMRKBNTXNVAX